Skip to main content
Top

Tip

Swipe om te navigeren naar een ander artikel

Gepubliceerd in: Quality of Life Research 12/2020

31-07-2020

Health-related quality of life in patients with non-functioning pituitary adenoma: a special focus on hydrocortisone replacement dose

Auteurs: Carl Mathis Wild, Mareike Stieg, Günter K. Stalla, Matthias K. Auer, Anastasia P. Athanasoulia-Kaspar

Gepubliceerd in: Quality of Life Research | Uitgave 12/2020

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail

Abstract

Purpose

Patients with non-functioning pituitary adenomas (NFPA) suffer from pronounced impairments in physical and mental measures that result in an impairment of health-related quality of life (HRQOL). The role of secondary adrenal insufficiency (SAI) and especially the one of the hydrocortisone (HC) replacement dose on the HRQOL seems to be conflicting. The primary aim of this study is to assess the HRQOL in patients with NFPA in terms of presence of SAI and in patients without SAI and the secondary to explore the impact of treatment parameters such as daily HC dose.

Design/Methods

In a cross-sectional study we evaluated parameters of HRQOL in 95 patients with NFPA of the Endocrine Outpatient Unit of the Max Planck Institute of Psychiatry in Munich using standardized questionnaires like Short Form (SF-36), Beck's Depression Inventory (BDI), State-Trait Anxiety Inventory (STAI), Epworth Sleepiness Scale (ESS), Pittsburgh Sleep Quality Index (PSQI) and a self-constructed questionnaire about medical history.

Results

We could not find any significant difference between patients with and without SAI in the standardized questionnaires in terms of HRQOL. We could show that higher doses of HC were negatively correlated with HRQOL measured by SF-36 global health score regardless of using BDI or STAI in the block (β =  − 0.397; p = 0.021, β =  − 0.390; p = 0.016, respectively).

Conclusions

NFPA patients with SAI do not have a worse HRQOL than patients with NFPA and intact corticotropic axis. We could show that higher doses of HC are associated with an impaired HRQOL measured by SF-36 global and physical health score, whereas mental health score is not significantly influenced by the HC dose.
Literatuur
1.
go back to reference Andela, C. D., Scharloo, M., Pereira, A. M., Kaptein, A. A., & Biermasz, N. R. (2015). Quality of life (QoL) impairments in patients with a pituitary adenoma: A systematic review of QoL studies. Pituitary, 18, 752–776. CrossRef Andela, C. D., Scharloo, M., Pereira, A. M., Kaptein, A. A., & Biermasz, N. R. (2015). Quality of life (QoL) impairments in patients with a pituitary adenoma: A systematic review of QoL studies. Pituitary, 18, 752–776. CrossRef
2.
go back to reference Leistner, S. M., Klotsche, J., Dimopoulou, C., et al. (2015). Reduced sleep quality and depression associate with decreased quality of life in patients with pituitary adenomas. European Journal of Endocrinology, 172, 733–743. CrossRef Leistner, S. M., Klotsche, J., Dimopoulou, C., et al. (2015). Reduced sleep quality and depression associate with decreased quality of life in patients with pituitary adenomas. European Journal of Endocrinology, 172, 733–743. CrossRef
3.
go back to reference van der Klaauw, A. A., Kars, M., Biermasz, N. R., et al. (2008). Disease-specific impairments in quality of life during long-term follow-up of patients with different pituitary adenomas. Clinical Endocrinology Oxford, 69, 775–784. CrossRef van der Klaauw, A. A., Kars, M., Biermasz, N. R., et al. (2008). Disease-specific impairments in quality of life during long-term follow-up of patients with different pituitary adenomas. Clinical Endocrinology Oxford, 69, 775–784. CrossRef
4.
go back to reference Ragnarsson, O., Mattsson, A. F., Monson, J. P., et al. (2014). The relationship between glucocorticoid replacement and quality of life in 2737 hypopituitary patients. European Journal of Endocrinology, 171, 571–579. CrossRef Ragnarsson, O., Mattsson, A. F., Monson, J. P., et al. (2014). The relationship between glucocorticoid replacement and quality of life in 2737 hypopituitary patients. European Journal of Endocrinology, 171, 571–579. CrossRef
5.
go back to reference Milian, M., Honegger, J., Gerlach, C., & Psaras, T. (2013). Health-related quality of life and psychiatric symptoms improve effectively within a short time in patients surgically treated for pituitary tumors—A longitudinal study of 106 patients. Acta Neurochirurgica, 155, 1637–1645. CrossRef Milian, M., Honegger, J., Gerlach, C., & Psaras, T. (2013). Health-related quality of life and psychiatric symptoms improve effectively within a short time in patients surgically treated for pituitary tumors—A longitudinal study of 106 patients. Acta Neurochirurgica, 155, 1637–1645. CrossRef
6.
go back to reference Tiemensma, J., Andela, C. D., Kaptein, A. A., et al. (2014). Psychological morbidity and impaired quality of life in patients with stable treatment for primary adrenal insufficiency: CROSS-sectional study and review of the literature. European Journal of Endocrinology, 171, 171–182. CrossRef Tiemensma, J., Andela, C. D., Kaptein, A. A., et al. (2014). Psychological morbidity and impaired quality of life in patients with stable treatment for primary adrenal insufficiency: CROSS-sectional study and review of the literature. European Journal of Endocrinology, 171, 171–182. CrossRef
7.
go back to reference Hahner, S., Loeffler, M., Fassnacht, M., et al. (2007). Impaired subjective health status in 256 patients with adrenal insufficiency on standard therapy based on cross-sectional analysis. The Journal of Clinical Endocrinology and Metabolism, 92, 3912–3922. CrossRef Hahner, S., Loeffler, M., Fassnacht, M., et al. (2007). Impaired subjective health status in 256 patients with adrenal insufficiency on standard therapy based on cross-sectional analysis. The Journal of Clinical Endocrinology and Metabolism, 92, 3912–3922. CrossRef
8.
go back to reference Danilowicz, K., Bruno, O. D., Manavela, M., Gomez, R. M., & Barkan, A. (2008). Correction of cortisol overreplacement ameliorates morbidities in patients with hypopituitarism: A pilot study. Pituitary, 11, 279–285. CrossRef Danilowicz, K., Bruno, O. D., Manavela, M., Gomez, R. M., & Barkan, A. (2008). Correction of cortisol overreplacement ameliorates morbidities in patients with hypopituitarism: A pilot study. Pituitary, 11, 279–285. CrossRef
9.
go back to reference Wichers, M., Springer, W., Bidlingmaier, F., & Klingmuller, D. (1999). The influence of hydrocortisone substitution on the quality of life and parameters of bone metabolism in patients with secondary hypocortisolism. Clinical Endocrinology Oxford, 50, 759–765. CrossRef Wichers, M., Springer, W., Bidlingmaier, F., & Klingmuller, D. (1999). The influence of hydrocortisone substitution on the quality of life and parameters of bone metabolism in patients with secondary hypocortisolism. Clinical Endocrinology Oxford, 50, 759–765. CrossRef
10.
go back to reference Karppinen, A., Ritvonen, E., Roine, R., et al. (2016). Health-related quality of life in patients treated for non-functioning pituitary adenomas during the years 2000–2010. Clinical Endocrinology Oxford, 84(4), 532–539. CrossRef Karppinen, A., Ritvonen, E., Roine, R., et al. (2016). Health-related quality of life in patients treated for non-functioning pituitary adenomas during the years 2000–2010. Clinical Endocrinology Oxford, 84(4), 532–539. CrossRef
11.
go back to reference Romijn, J., Smit, J., & Lamberts, S. (2003). Intrinsic imperfections of endocrine replacement therapy. European Journal of Endocrinology, 149, 91–97. CrossRef Romijn, J., Smit, J., & Lamberts, S. (2003). Intrinsic imperfections of endocrine replacement therapy. European Journal of Endocrinology, 149, 91–97. CrossRef
12.
go back to reference Hahner, S., Loeffler, M., Bleicken, B., et al. (2010). Epidemiology of adrenal crisis in chronic adrenal insufficiency: The need for new prevention strategies. European Journal of Endocrinology, 162, 597–602. CrossRef Hahner, S., Loeffler, M., Bleicken, B., et al. (2010). Epidemiology of adrenal crisis in chronic adrenal insufficiency: The need for new prevention strategies. European Journal of Endocrinology, 162, 597–602. CrossRef
13.
go back to reference Peacey, S. R., Guo, C. Y., Robinson, A. M., et al. (1997). Glucocorticoid replacement therapy: Are patients over treated and does it matter? Clinical Endocrinology Oxford, 46, 255–261. CrossRef Peacey, S. R., Guo, C. Y., Robinson, A. M., et al. (1997). Glucocorticoid replacement therapy: Are patients over treated and does it matter? Clinical Endocrinology Oxford, 46, 255–261. CrossRef
14.
go back to reference Løvås, K., Gjesdal, C. G., Christensen, M., et al. (2009). Glucocorticoid replacement therapy and pharmacogenetics in Addison's disease: Effects on bone. European Journal of Endocrinology, 160, 993–1002. CrossRef Løvås, K., Gjesdal, C. G., Christensen, M., et al. (2009). Glucocorticoid replacement therapy and pharmacogenetics in Addison's disease: Effects on bone. European Journal of Endocrinology, 160, 993–1002. CrossRef
15.
go back to reference Filipsson, H., Monson, J. P., Koltowska-Haggstrom, M., Mattsson, A., & Johannsson, G. (2006). The impact of glucocorticoid replacement regimens on metabolic outcome and comorbidity in hypopituitary patients. The Journal of Clinical Endocrinology and Metabolism, 91, 3954–3961. CrossRef Filipsson, H., Monson, J. P., Koltowska-Haggstrom, M., Mattsson, A., & Johannsson, G. (2006). The impact of glucocorticoid replacement regimens on metabolic outcome and comorbidity in hypopituitary patients. The Journal of Clinical Endocrinology and Metabolism, 91, 3954–3961. CrossRef
16.
go back to reference Esteban, N. V., & Yergey, A. L. (1990). Cortisol production rates measured by liquid chromatography/mass spectrometry. Steroids, 55, 152–158. CrossRef Esteban, N. V., & Yergey, A. L. (1990). Cortisol production rates measured by liquid chromatography/mass spectrometry. Steroids, 55, 152–158. CrossRef
17.
go back to reference Linder, B. L., Esteban, N. V., Yergey, A. L., Winterer, J. C., Loriaux, D. L., & Cassorla, F. (1990). Cortisol production rate in childhood and adolescence. The Journal of Pediatrics, 117, 892–896. CrossRef Linder, B. L., Esteban, N. V., Yergey, A. L., Winterer, J. C., Loriaux, D. L., & Cassorla, F. (1990). Cortisol production rate in childhood and adolescence. The Journal of Pediatrics, 117, 892–896. CrossRef
18.
go back to reference Ware, J. E., Jr., & Sherbourne, C. D. (1992). The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Medical Care, 30, 473–483. CrossRef Ware, J. E., Jr., & Sherbourne, C. D. (1992). The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Medical Care, 30, 473–483. CrossRef
19.
go back to reference Kühner, C., Bürger, C., Keller, F., & Hautzinger, M. (2007). Reliability and validity of the revised beck depression inventory (BDI-II). Der Nervenarzt, 78, 651–656. CrossRef Kühner, C., Bürger, C., Keller, F., & Hautzinger, M. (2007). Reliability and validity of the revised beck depression inventory (BDI-II). Der Nervenarzt, 78, 651–656. CrossRef
20.
go back to reference Wang, Y.-P., & Gorenstein, C. (2013). Psychometric properties of the beck depression inventory-II: A comprehensive review. Revista Brasileira de Psiquiatria, 35, 416–431. CrossRef Wang, Y.-P., & Gorenstein, C. (2013). Psychometric properties of the beck depression inventory-II: A comprehensive review. Revista Brasileira de Psiquiatria, 35, 416–431. CrossRef
21.
go back to reference Bieling, P. J., Antony, M. M., & Swinson, R. P. (1998). The state-trait anxiety inventory, trait version: Structure and content re-examined. Behaviour Research and Therapy, 36, 777–788. CrossRef Bieling, P. J., Antony, M. M., & Swinson, R. P. (1998). The state-trait anxiety inventory, trait version: Structure and content re-examined. Behaviour Research and Therapy, 36, 777–788. CrossRef
22.
go back to reference Caci, H., Baylé, F. J., Dossios, C., Robert, P., & Boyer, P. (2003). The Spielberger trait anxiety inventory measures more than anxiety. European Psychiatry, 18, 394–400. CrossRef Caci, H., Baylé, F. J., Dossios, C., Robert, P., & Boyer, P. (2003). The Spielberger trait anxiety inventory measures more than anxiety. European Psychiatry, 18, 394–400. CrossRef
23.
go back to reference Buysse, D. J., Reynolds, C. F., 3rd, Monk, T. H., Berman, S. R., & Kupfer, D. J. (1989). The pittsburgh sleep quality index: A new instrument for psychiatric practice and research. Psychiatry Research, 28, 193–213. CrossRef Buysse, D. J., Reynolds, C. F., 3rd, Monk, T. H., Berman, S. R., & Kupfer, D. J. (1989). The pittsburgh sleep quality index: A new instrument for psychiatric practice and research. Psychiatry Research, 28, 193–213. CrossRef
24.
go back to reference Johns, M. W. (1991). A new method for measuring daytime sleepiness: The Epworth sleepiness scale. Sleep, 14, 540–545. CrossRef Johns, M. W. (1991). A new method for measuring daytime sleepiness: The Epworth sleepiness scale. Sleep, 14, 540–545. CrossRef
25.
go back to reference Johns, M. (1998). Rethinking the assessment of sleepiness. Sleep Medicine Reviews, 2, 3–15. CrossRef Johns, M. (1998). Rethinking the assessment of sleepiness. Sleep Medicine Reviews, 2, 3–15. CrossRef
26.
go back to reference Ritvonen, E., Karppinen, A., Sintonen, H., et al. (2015). Normal long-term health-related quality of life can be achieved in patients with functional pituitary adenomas having surgery as primary treatment. Clinical Endocrinology Oxford, 82, 412–421. CrossRef Ritvonen, E., Karppinen, A., Sintonen, H., et al. (2015). Normal long-term health-related quality of life can be achieved in patients with functional pituitary adenomas having surgery as primary treatment. Clinical Endocrinology Oxford, 82, 412–421. CrossRef
27.
go back to reference Kluger, N., Matikainen, N., Sintonen, H., Ranki, A., Roine, R. P., & Schalin-Jantti, C. (2014). Impaired health-related quality of life in Addison's disease—impact of replacement therapy, comorbidities and socio-economic factors. Clinical Endocrinology Oxford, 81, 511–518. CrossRef Kluger, N., Matikainen, N., Sintonen, H., Ranki, A., Roine, R. P., & Schalin-Jantti, C. (2014). Impaired health-related quality of life in Addison's disease—impact of replacement therapy, comorbidities and socio-economic factors. Clinical Endocrinology Oxford, 81, 511–518. CrossRef
28.
go back to reference Bleicken, B., Hahner, S., Loeffler, M., et al. (2010). Influence of hydrocortisone dosage scheme on health-related quality of life in patients with adrenal insufficiency. Clinical Endocrinology, 72, 297–304. CrossRef Bleicken, B., Hahner, S., Loeffler, M., et al. (2010). Influence of hydrocortisone dosage scheme on health-related quality of life in patients with adrenal insufficiency. Clinical Endocrinology, 72, 297–304. CrossRef
29.
go back to reference Morgan, S. A., Hassan-Smith, Z. K., & Lavery, G. G. (2016). Mechanisms in endocrinology: Tissue-specific activation of cortisol in Cushing's syndrome. European Journal of Endocrinology, 175(2), R83–R89. CrossRef Morgan, S. A., Hassan-Smith, Z. K., & Lavery, G. G. (2016). Mechanisms in endocrinology: Tissue-specific activation of cortisol in Cushing's syndrome. European Journal of Endocrinology, 175(2), R83–R89. CrossRef
30.
go back to reference Isidori, A. M., Venneri, M. A., Graziadio, C., et al. (2018). Effect of once-daily, modified-release hydrocortisone versus standard glucocorticoid therapy on metabolism and innate immunity in patients with adrenal insufficiency (DREAM): A single-blind, randomised controlled trial. Lancet Diabetes Endocrinology, 6(3), 173–185. CrossRef Isidori, A. M., Venneri, M. A., Graziadio, C., et al. (2018). Effect of once-daily, modified-release hydrocortisone versus standard glucocorticoid therapy on metabolism and innate immunity in patients with adrenal insufficiency (DREAM): A single-blind, randomised controlled trial. Lancet Diabetes Endocrinology, 6(3), 173–185. CrossRef
Metagegevens
Titel
Health-related quality of life in patients with non-functioning pituitary adenoma: a special focus on hydrocortisone replacement dose
Auteurs
Carl Mathis Wild
Mareike Stieg
Günter K. Stalla
Matthias K. Auer
Anastasia P. Athanasoulia-Kaspar
Publicatiedatum
31-07-2020
Uitgeverij
Springer International Publishing
Gepubliceerd in
Quality of Life Research / Uitgave 12/2020
Print ISSN: 0962-9343
Elektronisch ISSN: 1573-2649
DOI
https://doi.org/10.1007/s11136-020-02582-7

Andere artikelen Uitgave 12/2020

Quality of Life Research 12/2020 Naar de uitgave